Biomarkers for Therapy Response in Drug-resistant Tuberculosis

Research Center Borstel192 enrolled

Overview

Multi-center, observational, prospective cohort study including patients with multidrug-resistant tuberculosis at different sites in Germany. The aim the study is the identification of biomarkers for therapy response.

The increasing rates of multidrug-resistant (MDR) tuberculosis (TB) are causing great concern. The current study that will be conducted at different centers in Germany. Biomarkers for treatment response during the course of the tuberculosis therapy will be evaluated. The study will be conducted with funding of the German Center for Infection Research (DZIF).

Study Type

OBSERVATIONAL

Enrollment

192

Conditions

Tuberculosis, Multidrug-resistant

Interventions

no interventionOTHER

no intervention

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with confirmed pulmonary MDR-TB * Subject able and willing to give informed consent Exclusion Criteria: * HIV infection * physical or mental inability preventing study participation at the discretion of the investigator * member of a vulnerable or special population (prisoner, soldier, mentally ill, under guardianship) * age \<18 years.

Locations (1)

Research Center Borstel

Borstel, Schleswig-Holstein, Germany

Outcomes

Primary Outcomes

Identification of biomarkers for therapy response

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.